One-Dose HPV Vaccination Averts Similar Number of Cancers as Two Doses
By Elana Gotkine HealthDay Reporter
MONDAY, Oct. 7, 2024 -- A one-dose human papillomavirus (HPV) vaccination program is projected to prevent a similar number of cervical cancers as a two-dose program, according to a study published online Oct. 7 in CMAJ, the journal of the Canadian Medical Association.
Mélanie Drolet, Ph.D., from the Université Laval in Québec City, and colleagues used an individual-based transmission-dynamic model of HPV infections and diseases to mathematically model vaccination programs in two provinces: Quebec, with around 85 percent vaccination coverage, and Ontario, with around 65 percent coverage. The authors sought to project the population-level impact and efficiency of switching from two- to one-dose, gender-neutral, routine HPV vaccination.
The researchers projected that under various scenarios, one-dose HPV vaccination would avert a similar number of cervical cancers as two doses in Canada. Under the most pessimistic scenario (vaccine duration, 25 years), one dose would avert fewer cervical cancer cases than two doses, with a difference of about 3 percentage points over 100 years. Elimination of cervical cancer was projected with all one-dose scenarios (fewer than four cervical cancers/100,000 female-years), and one dose was considered to be a substantially more efficient use of vaccine doses than two doses.
"One-dose vaccination represents a more efficient use of vaccine doses and is projected to lead to elimination of cervical cancer in Canada," the authors write. "Continued monitoring of one-dose protection over time is required to rapidly detect any signs of waning one-dose efficacy."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
35 Percent of Eligible Children Receive RSV Prophylaxis With Nirsevimab
TUESDAY, July 22, 2025 -- Despite near universal availability of nirsevimab, only 35 percent of eligible children receive nirsevimab for respiratory syncytial virus (RSV)...
Updated Guidance Improves Staging of HPV-Positive Oropharyngeal Cancer
MONDAY, July 21, 2025 -- Version nine of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control staging system (AJCC9V) human papillomavirus...
2020 to 2024 Saw Drop in Flu Vaccine Uptake Among U.S. Adults
FRIDAY, July 18, 2025 -- There was an overall decrease in influenza vaccine uptake among U.S. adults from 2020 to 2024, according to a study published online July 16 in PLOS...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.